The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•31 March 2026•

1 min read

Xtant Medical Swings to Profitability as 2025 Revenue Climbs 14%

3D metallic 'PVH' text with 'CALVIN KLEIN' and 'TOMMY HILFIGER' names. Upward trend line, 'EARNINGS BEAT', 'REVENUE: +14%', and '2026 GUIDANCE' on an orange background.

Key Facts

1Xtant Medical achieved full-year 2025 revenue of $133.9 million, a 14% increase year-over-year.

2The company swung to a positive net income of $5.0 million for the full year, compared to a net loss in the prior year.

Xtant Medical Holdings (XTNT) reported strong financial results for the fourth quarter and full fiscal year 2025, highlighted by a 14% year-over-year increase in annual revenue to $133.9 million. The company achieved a significant milestone by swinging to a positive net income of $5.0 million for the full year, a marked improvement from the net loss recorded in the previous year. Fourth-quarter revenue reached $32.4 million, exceeding analyst estimates and reflecting strong demand for the company's core biologics portfolio. The financial position was further bolstered by a final $10.7 million payment received in early 2026 from the divestiture of Companion Spine assets. CEO Sean Browne attributed the performance to operational efficiencies and a strategic focus on high-margin products. These results signal a successful turnaround for the medical technology firm, positioning it for continued growth in the biologics sector.